Visgib 150mg (Vismodegib) is a targeted therapy drug manufactured by Pharma Lord, primarily used for treating advanced basal cell carcinoma (BCC). Vismodegib is a hedgehog pathway inhibitor that works by blocking a crucial signaling pathway (Hedgehog pathway) responsible for the growth and survival of cancer cells in BCC. By inhibiting this pathway, Vismodegib reduces tumor growth and promotes cancer cell death.
Advantages of Vismodegib:
- Effective for Advanced BCC: Vismodegib is highly effective in treating locally advanced or metastatic basal cell carcinoma that cannot be treated with surgery or radiation.
- Hedgehog Pathway Inhibition: It specifically targets and inhibits the Hedgehog signaling pathway, which is essential for the survival of certain cancer cells, leading to their destruction.
- Oral Convenience: The drug is administered orally, providing convenience and ease of use for patients compared to other treatment options.
- Minimal Invasive Option: Vismodegib offers a non-invasive treatment option for patients with advanced BCC, especially when surgery is not viable.
- Promotes Tumor Shrinkage: It effectively shrinks basal cell carcinoma tumors, improving patient outcomes.
Uses of Visgib 150mg:
- Basal Cell Carcinoma (BCC): Primarily used for treating locally advanced or metastatic basal cell carcinoma in patients where surgery or radiation therapy is not suitable.
- Recurrent BCC: Effective in managing cases of recurrent basal cell carcinoma after prior treatments have failed.